PharmaEngine announces first patient dosed in PEP08 Phase I clinical trial for solid tumor cancers

PharmaEngine recognized as one of 2025 Taiwan Best-in-Class Companies by Taiwan Institute of Directors

PharmaEngine announces TFDA approval of PEP08 Phase 1 clinical trial for solid tumor cancers

PharmaEngine announces Phase I clinical study of PEP08 has been approved by Australia HREC and acknowledged by Australia TGA

PharmaEngine to present three posters in AACR 2025

PharmaEngine to receive US$50 million in milestone payment as ONIVYDE's 2024 sales in Europe and Asia had reached second milestone

PharmaEngine and Haihe Biopharma enter into exclusive distribution agreement for LIPORAXEL®

PharmaEngine announces first patient dosed in Phase I trial of PEP07 for solid tumor cancers

ONIVYDE® obtains positive opinion from EMA's CHMP for new regimen in First-line Treatment of Metastatic PDAC

ONIVYDE® obtains TFDA Approval for the new regimen in First-line Treatment of Metastatic PDAC